Evidence map›Paper›PMID 29177570›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2018

Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.

Mari Yokoi, Daiki Tsuji, Kenichi Suzuki, Yohei Kawasaki, Masahiko Nakao, Hideaki Ayuhara, Yuuki Kogure, Kazuhiko Shibata, Toshinobu Hayashi, Keita Hirai and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Mari YokoiDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
Daiki TsujiDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan. d-tsuji@u-shizuoka-ken.ac.jp.
Kenichi SuzukiDepartment of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
Yohei KawasakiDepartment of Drug Evaluation and Informatics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Masahiko NakaoDepartment of Pharmacy, Osaka City General Hospital, Osaka, Japan.
Hideaki AyuharaDepartment of Pharmacy, Tokyo Medical University Hospital, Tokyo, Japan.
Yuuki KogureDepartment of Pharmacy, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Kazuhiko ShibataDepartment of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Japan.
Toshinobu HayashiDepartment of Pharmacy, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Keita HiraiDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
Kazuyuki InoueDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
Toshihiro HamaDepartment of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
Koji TakedaDepartment of Clinical Oncology, Osaka City General Hospital, Osaka, Japan.
Makoto NishioDepartment of Thoracic Medical Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
Kunihiko ItohDepartment of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
University of Shizuoka · JPJapanese Foundation For Cancer Research · JPOsaka City General Hospital · JPKouseiren Takaoka Hospital · JPNational Kyushu Medical Center · JPShikoku Cancer Center · JPTokyo Medical University Hospital · JP

Funding

JSPS KAKENHI 26860110
6 · The paper itself

Abstract

purposeYounger age and female sex have already been well-known risk factors for chemotherapy-induced nausea and vomiting (CINV), and 30-50% of cancer patients still suffer from CINV. Genetic polymorphisms are suggested to influence antiemetic treatment response.

methodsThis study included a subset of patients previously enrolled in a randomised controlled trial; 156 patients were evaluated. This study aimed to evaluate the role of pharmacogenomic polymorphisms relevant to antiemetic response in patients with cancer receiving cisplatin-based chemotherapy. The study's efficacy endpoint was the proportion of patients with complete response (CR). The study endpoint was evaluated separately in the acute (CR

resultsMultivariate logistic regression analysis revealed that the ERCC1 8092AA (odds ratio [OR] = 11.25; 95% confidence interval [CI] 1.74-72.71; p = 0.011) and female sex (OR = 3.63; 95% CI 1.14-11.58; p = 0.029) were significant predictors of CR

conclusionsERCC1 polymorphism influenced the extent of CINV control in patients receiving cisplatin-based chemotherapy.

trial registrationClinical trial information: UMIN 000009335.

Indexed as

AdultAgedAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials, Phase III as TopicDexamethasoneFemaleGenetic Predisposition to DiseaseGranisetronHumansMaleMiddle AgedNauseaNeoplasmsPalonosetronAntiemeticsCisplatinDexamethasoneGranisetronPalonosetronAprepitantChemotherapy-induced nausea and vomiting (CINV)CisplatinERCC1 polymorphismGranisetronPalonosetron

Identifiers

PMID29177570
OpenAlexW2768596359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.